ReviewPediatric research2018
Umbilical cord blood cells for treatment of cerebral palsy; timing and treatment options.
Review in Pediatric research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 5 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Hybrid umbilical cord blood banking: literature review.Archives of gynecology and obstetrics · 2024Pooled it
- Allogeneic Cell Therapy Applications in Neonates: A Systematic Review.Stem cells translational medicine · 2023Pooled it
- A systematic review of neuroimaging epigenetic research: calling for an increased focus on development.Molecular psychiatry · 2023Pooled it
- Umbilical Cord Blood and Cord Tissue-Derived Cell Therapies for Neonatal Morbidities: Current Status and Future Challenges.Stem cells translational medicine · 2022Pooled it
- Neural stem cell treatment for perinatal brain injury: A systematic review and meta-analysis of preclinical studies.Stem cells translational medicine · 2021Pooled it
- Maintenance of the synergistic effects of cord blood cells and erythropoietin combination therapy after additional cord blood infusion in children with cerebral palsy: 1-year open-label extension study of randomized placebo-controlled trial.Stem cell research & therapy · 2023Trial
- Bone Marrow Mesenchymal Stem Cells in Acute-on-Chronic Liver Failure Grades 2 and 3: A Phase I-II Randomized Clinical Trial.Canadian journal of gastroenterology & hepatology · 2021Trial
- Umbilical cord milking as a technique to harvest cord blood derived cells for regenerative applications.Pediatric research · 2026Article
- REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial.EClinicalMedicine · 2026Article
- Umbilical Cord Blood Endothelial Progenitor Cells Modulate Neurovascular Unit Damage in a Neonatal Rat Model of Hypoxia Ischemia.Stem cell reviews and reports · 2025Article
- Article
- Implementation of a novel hybrid cord blood banking model within a private-public-partnership.Transfusion · 2025Article
- Effects of fetal growth restriction on the perinatal neurovascular unit and possible treatment targets.Pediatric research · 2024Review
- Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury.Stem cells translational medicine · 2023Article
- Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives.Biology · 2022Review
- Comparison of the therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells and adipose-derived stem cells on erectile dysfunction in a rat model of bilateral cavernous nerve injury.Frontiers in bioengineering and biotechnology · 2022Article
- Stem Cell Therapies for Cerebral Palsy and Autism Spectrum Disorder-A Systematic Review.Brain sciences · 2021Review
- Synergistic Effect in Neurological Recovery via Anti-Apoptotic Akt Signaling in Umbilical Cord Blood and Erythropoietin Combination Therapy for Neonatal Hypoxic-Ischemic Brain Injury.International journal of molecular sciences · 2021Article
- Influences of Xeno-Free Media on Mesenchymal Stem Cell Expansion for Clinical Application.Tissue engineering and regenerative medicine · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral palsy is the most common cause of physical disability in children, and there is no cure. Umbilical cord blood (UCB) cell therapy for the treatment of children with cerebral palsy is currently being assessed in clinical trials. Although there is much interest in the use of UCB stem cells for neuroprotection and neuroregeneration, the mechanisms of action are not fully understood. Further, UCB contains many stem and progenitor cells of interest, and we will point out that individual cell types within UCB may elicit specific effects. UCB is a clinically proven source of hemotopoietic stem cells (HSCs). It also contains mesenchymal stromal cells (MSCs), endothelial progenitor cells (EPCs), and immunosupressive cells such as regulatory T cells (Tregs) and monocyte-derived supressor cells. Each of these cell types may be individual candidates for the prevention of brain injury following hypoxic and inflammatory events in the perinatal period. We will discuss specific properties of cell types in UCB, with respect to their therapeutic potential and the importance of optimal timing of administration. We propose that tailored cell therapy and targeted timing of administration will optimize the results for future clinical trials in the neuroprotective treatment of perinatal brain injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.